An experimental oral treatment called taladegib helped expand lung volume and reduce scarring in people with idiopathic pulmonary fibrosis (IPF), according to a new imaging analysis from a clinical trial. Data from the Phase 2a trial (NCT04968574), generated using artificial intelligence (AI) to evaluate high-resolution chest scans, were…
Discussion
Note: This column was updated Sept. 18, 2026, to correct that ILDs are restrictive diseases, while chronic obstructive pulmonary disease and asthma are obstructive diseases. Because idiopathic pulmonary fibrosis (IPF) is a diagnosis of exclusion, it’s easy to forget about all of the other related diseases that make up…
Discussion
The U.S. Food and Drug Administration (FDA) will decide by early next year whether or not to expand its approval of nebulized Tyvaso (treprostinil) — an inhaled treatment for people with certain lung diseases — to allow its use in idiopathic pulmonary fibrosis (IPF), a respiratory condition marked…
Becoming educated and informed about PF is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your PF journey.
There is no cure for PF yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
